News Releases

Emiltatug Ledadotin (Emi-Le) Granted Breakthrough Therapy Designation by the U.S. FDA for Adenoid Cystic Carcinoma (ACC)

Day One and Servier Complete Enrollment in Pivotal Phase 3 FIREFLY-2 Trial of Tovorafenib as a Front-Line Treatment for Pediatric Low-Grade Glioma (pLGG)

Servier completes the acquisition of Day One Biopharmaceuticals

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio

Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030

Servier's Clinical and Real-World Data at 2025 SNO Congress Showcase Leadership in IDH-Mutant Glioma

Servier's New and Updated Data at 2025 ASH Annual Meeting Highlight Commitment to Hematology Research

Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The Lancet Oncology

Servier's VORANIGO® (vorasidenib) Receives Prestigious 2025 Prix Galien USA Award

European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU